

## Supporting Information

### **hBfl-1/hNOXA interaction studies provide new insights on the role of Bfl-1 in cancer cell resistance and for the design of novel apoptosis-based therapeutics**

Elisa Barile,<sup>1</sup> Guya D. Marconi,<sup>1</sup> Surya K. De,<sup>1</sup> Carlo Baggio,<sup>1</sup> Luca Gambini,<sup>1</sup>  
Ahmed F. Salem,<sup>1</sup> Manoj K. Kashyap,<sup>2,3</sup> Januario E. Castro,<sup>2,3</sup> Thomas J.  
Kipps,<sup>2,3</sup> and Maurizio Pellecchia<sup>1,\*</sup>

1. Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, CA 92521, USA.
2. Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA
3. CLL Research Consortium, and Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA

\* Corresponding author: Maurizio Pellecchia, phone number: **(951)-827-7829**;  
email address: [maurizio.pellecchia@ucr.edu](mailto:maurizio.pellecchia@ucr.edu)

**Table S1:** Aminoacid sequences, and corresponding molecular weights of hNOXA and hBIM derived peptides reported in Tables 1 and 2.

Compd ID	aa sequence	MW
<b>hNOXA</b>	Ac-CATQLRRFGDKLNFRQKLLN-NH <sub>2</sub>	2463.02
<b>homo_hNOXA</b>	Ac-hCATQLRRFGDKLNFRQKLLN-NH <sub>2</sub>	2476.77
<b>λ_hNOXA</b>	Ac-λATQLRRFGDKLNFRQKLLN-NH <sub>2</sub>	2521.07
<b>hNOXAs</b>	Ac-CATQLRRFGDKLN-NH <sub>2</sub>	1561.83
<b>NOXA A</b>	Ac-AELPPEFAAQLRKIGDKVYC-NH <sub>2</sub>	2288.19
<b>NOXA B</b>	Ac-PADLKDECAQLRRIGDKVNL-NH <sub>2</sub>	2294.21
<b>C1A_hNOXAs</b>	Ac-AATQLRRFGDKLN-NH <sub>2</sub>	1529.84
<b>cyc_hNOXA</b>	Ac-CATQLRRFGDKLNFRQKLLNLISKLFC-NH <sub>2</sub>	3366.94
<b>hBIM</b>	Ac-IWIAQELRRIGDEFNAYYARR-NH <sub>2</sub>	2682.15
<b>130E7</b>	Ac-λIAQELRRIGDEFNAYYARR-NH <sub>2</sub>	2545.51
<b>130D11</b>	Ac-λAQELRX <sub>i</sub> IGDX <sub>i+4</sub> FNAYYARR-NH <sub>2</sub>	2511.53
<b>130G4</b>	Ac-(PRR) <sub>5</sub> λIAQELRRIGDEFNAYYARR-NH <sub>2</sub>	4593.32


hC  
=  
hom  
ocy  
stei  
ne;  
λ  
=Da  
p(2-  
chlo  
roac  
eta  
mid  
e);  
C1-  
C27  
in  
cyc-

NOXA = disulfide bridge

**Table S2:** *K<sub>d</sub>* values derived by Isothermal Titration Calorimetry (ITC) measurements for the selected peptides against hBcl-xL, hMcl-1 and hBfl-1. Isothermal titration calorimetry measurements were performed using a VP-ITC calorimeter from Microcal (Northampton, MA, USA). Measurements were performed in a reverse fashion (i.e., the protein was titrated into the compound solution). All titrations were performed at 25°C in PBS buffer supplemented with 10% DMSO. Experimental data were analyzed using Microcal Origin software provided by the ITC manufacturer (Microcal).

Compd ID	ITC <i>K<sub>d</sub></i> (nM)		
	hBcl-X <sub>L</sub>	hMcl-1	hBfl-1
<b>130E7</b>	25.5	2.0	2.6
<b>130D11</b>	No Binding	No Binding	No Binding
<b>130G4</b>	12.7	11.6	23.0

**Figure S1:** Dose-response DELFIA assay curves used to characterize the binding affinities of hNOXAs and hNOXAs\_C1A peptides for their ability to displace a BID peptide from hBfl-1. Dose response curves are the results of duplicate measurements. The relative IC<sub>50</sub> values are reported in Table 1.



**Figure S2:** SDS-PAGE gel electrophoresis followed by Coomassie staining of hBfl-1 (10  $\mu$ M) in absence and presence of equimolar concentrations of homo\_hNOXA (Panel A, Table 1, Table S1)  $\lambda$ \_hNOXA (Panel B, Table 1, Table S1) and 130G4 (Panel C, Table 1, Table S1) at different time points (15', 30', 1h, 2h).

